Sign up to save your podcasts
Or
Share Rosie Bradley on early-stage breast cancer treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Rosie Bradley on early-stage breast cancer treatment
Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.
Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.
Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Oncology in conversation with
View all
Global News Podcast
7,708 Listeners
NEJM This Week
319 Listeners
The Daily
112,942 Listeners
OncoPharm
187 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
anything goes with emma chamberlain
62,557 Listeners
The Uromigos
57 Listeners
The Lancet Voice
20 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
EHA Unplugged
1 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
What Did You Do Yesterday? with Max Rushden & David O'Doherty
221 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners